JANX · Janux Therapeutics, Inc.

Track JANX — free

$16.54 -0.39 (-2.30%)

Russell 2000 member Rebalance outlook locked

Market Cap

$996.53M

61.14M

Volume · Oct 5 533.76K Avg daily vol (3M) 847.72K

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$24.00M

Trailing 12 months

Net income (TTM)

−$102.59M

Trailing 12 months

Revenue growth YoY

-5.6%

Year over year

Operating margin

-598.1%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-4.2%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$970.91M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.7%

Year over year · more shares

Price change (1Y)

-27.4%

Trailing year

Short interest

9.6%

Latest settlement · 5.9 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +13%

above

Price vs 50-day avg −1%

below

RSI (14) 48

neutral

MACD trend Negative

52-week position 21%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −14%

trailing

6-month return +14%

trailing

YTD return +23%

this year

Relative strength +1%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $17 › 200d $15 — 50d above 200d

Institutional flow Accumulating

1 of 199 funds reported for Sep 30 · net +1.5K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

9.64% of float · ▼ -2.8% MoM · 5.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

199 holders — mid 3-yr range

Squeeze score 70

elevated · 0–100

Fundamentals

Poor

Revenue growth −6%

Y/Y

EPS growth −43%

Y/Y

Free cash flow $-83.3M

Quant / Vol

risk profile

Very High

Volatility 74%

annualized · 1-yr

Max drawdown −65%

past year

ATR 4.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+13% Bullish

Price vs 50-day avg

−1% Neutral

RSI (14)

48 Neutral

MACD trend

Negative Bearish

52-week position

21% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $17 › 200d $15 — 50d above 200d

Institutional flow Accumulating

1 of 199 funds reported for Sep 30 · net +1.5K sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

9.64% of float · ▼ -2.8% MoM · 5.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

199 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $12 Now $17 · 21% Range high $35

vs 200-day avg +13% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cash and cash equivalents and short-term investments	$970.9M	second quarter 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
JANX Janux Therapeutics, Inc. this stock	$996.53M	+22.7%	-5.6%	—	9.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

199

% held: 100.2%
Reported: 1 of 199
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

199

View

Short & Settlement

Short Interest Falling

Shares short

5.9M

Days to cover: 5.9d
Change: -171.6K sh

View

Short Volume

Short vol %

64%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

18.5K

Value: $336.7K
As of: Sep 1, 2026

View

Off-Exchange

Off-exchange %

43.6%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-113.6M

EPS diluted: $-1.83

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 11

View

Proposed Sales

Value

$56.9K

Shares: 4.1K
Filed: Jun 2, 2026

View

Exempt Offerings

Offering

$125.0M

Filed: Apr 30, 2021

View

Earnings & Events

Webcasts

Last webcast

Dec 1, 2025

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
JANX	+3.9%	-14.5%	+13.6%	-2.0%	+22.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+4.1%	-14.0%	+1.4%	-3.0%	+9.8%

Key facts CIK 1817713 CUSIP 47103J105 13F (30d) 4 filings 4 filers Visit website Investor relations

JANX · Janux Therapeutics, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance